| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Pacira Biosciences, Inc. (PCRX) has 15 insiders with recent SEC Form 4 filings, including 4 buys and 13 sells. PCRX is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 399.0K | $9.38M | - | |
| Other | 218.9K | $5.15M | - | |
| Other | 167.1K | $3.93M | -10,259 | |
| CFO | 118.3K | $2.78M | - | |
| VP | 62.3K | $1.46M | -6,115 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2019 | Scranton Richard | Chief Scientific Officer | Sale+OE | 15,510 | $43.21 | $670,187.10 | -43.6% | |
| Mar 6, 2019 | Kronenfeld Mark A. | Director | Buy | 1,700 | $38.97 | $66,244.00 | +9.5% | |
| Dec 13, 2018 | Wicki Andreas71 | Director | Sell | 14,527 | $46.84 | $680,495.61 | -0.8% | |
| Nov 19, 2018 | Wicki Andreas71 | Director | Sell | 990 | $47.08 | $46,605.34 | -0.1% | |
| Nov 19, 2018 | Pace Gary W66 | Director | Buy | 4,500 | $46.18 | $207,810.00 | +15.9% | |
| Nov 16, 2018 | Wicki Andreas71 | Director | Sell | 70,498 | $47.34 | $3,337,586.90 | -1.8% | |
| Nov 15, 2018 | Stack David M67 | CEO And Chairman | Sell | 15,000 | $47.39 | $710,801.10 | -5.7% | |
| Nov 12, 2018 | Wicki Andreas71 | Director | Sell | 5,478 | $49.83 | $272,980.24 | -0.5% | |
| Nov 9, 2018 | Wicki Andreas71 | Director | Sell | 58,245 | $51.11 | $2,977,090.72 | -2.7% | |
| Nov 7, 2018 | Pace Gary W66 | Director | Buy | 4,000 | $51.29 | $205,160.00 | +16.4% |